Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track OVID with free AI briefings, catalyst countdowns, and dilution alerts.

OVID · Ovid Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$161.4M Cash on Hand
28.9mo Cash Runway
Follow OVID by email Get an email when OVID reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about OVID, unsubscribe in one click. Privacy

📣 What OVID Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Gaboxadol Primary Disease or Condition Being Studied: Angelman Syndrome (AS) Phase 3 · NCT04106557 Completed
OV101 Fragile X Syndrome (FXS) Phase 2 · NCT03697161 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

OVID holds $161.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.7M/quarter from operations, an estimated runway of 28.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OVID files for a raise →

👥 Who Owns OVID

Insiders 7% Institutions (168 holders) 84.5% Public and other holders 8.5%
HolderTypeShares% of sharesAs of
Sirenia Capital Management LP Institution (13G, 5%+) 18,031,333 9.55% 2026-03-31
RA Capital Management, L.P. Institution (13G, 5%+) 15,968,626 8.46% 2026-09-30
Affinity Asset Advisors, LLC Institution (13G, 5%+) 15,143,728 8.02% 2026-06-30
Eventide Asset Management, LLC Institution (13G, 5%+) 11,812,241 6.26% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 10,822,672 5.73% 2026-06-30
TAKEDA PHARMACEUTICAL CO LTD
10% owner
Insider 8,781,996 4.65% 2025-12-08
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 7,114,114 3.77% 2025-11-28
Jeremy M Levin
Executive Chairman, Director · +2.69M options
Insider 3,770,509 2.00% 2026-03-23
Stelios Papadopoulos
Director · +155,000 options
Insider 217,578 0.12% 2026-04-07
Jeffrey A Rona
CBFO · +986,250 options
Insider 156,313 0.08% 2026-02-23
Charles Ross Carter
Chief Financial Officer
Insider 94,375 0.05% 2026-07-06
Margaret A. Alexander
President and CEO, Director · +2.73M options
Insider 61,750 0.03% 2026-02-23

Share count 188,731,914 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full OVID picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OVID and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.